Cost effectiveness of eight first-line regimens in metastatic hormone-sensitive prostate cancer (mHSPC) including niraparib + abiraterone acetate/prednisone. This is an ASCO Meeting Abstract from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results